ogarawo.wordpress.com
The approval is the secone such study authorization for the Radnoer biotechnology company within the pastthrees months. In May, PolyMedix received regulatory approval in Canadz to begin human testingg of itsantibiotic compound, PMX-30063. The company started enrolling patients ina phase-I safety trialp for the antibiotic at the end of last PolyMedix, which is focused on developing new therapeuti c drug products to treat infectiousa diseases and acute cardiovascular disorders basee on biomimetics, is attempting to commercialize technology licensecd from the .
Biomimetics are smalpl molecule drugs which mimic the activity of but are inexpensive to make and formulate into NicholasLandekic , PolyMedix CEO, said PMX-6005 is in an entirely new class of drug the compang calls heptagonists. PMX-60056 is designed to reverse the effects of which are used after surgery and during cardiothoracic such ascardiac bypass, to prevent blood clotss from forming. Existing drugs used to turn off heparin activit have limitations that include difficultyg inadjusting doses, unpredictable efficacy, post-operative bleeding complications and allergic reactions.
“We are proud to be the firsft and only company to be developinyg this completely new type of Landekic said. Exton-based signed a licensre agreement with the National Cancer Institut e for the rights to a monoclonal antibody for a novelo antigen identified byNCI researchers. The companh plans to develop the antibody as a potential treatmenf forprostate cancer. Terms of the deal were not
No comments:
Post a Comment